Daily Cosmetic Research Analysis
Across cosmetic and aesthetic dermatology, three studies stand out: a scoping review maps the broad applications and combination strategies of radiofrequency microneedling (RFM) for facial rejuvenation; a 1-year cohort suggests pimecrolimus 1% cream can partially reverse topical corticosteroid-induced facial skin damage; and a comparative cohort shows PRP plus hyaluronic acid mesotherapy improves chloasma more than single-modality treatment with good short-term safety.
Summary
Across cosmetic and aesthetic dermatology, three studies stand out: a scoping review maps the broad applications and combination strategies of radiofrequency microneedling (RFM) for facial rejuvenation; a 1-year cohort suggests pimecrolimus 1% cream can partially reverse topical corticosteroid-induced facial skin damage; and a comparative cohort shows PRP plus hyaluronic acid mesotherapy improves chloasma more than single-modality treatment with good short-term safety.
Research Themes
- Energy-based skin rejuvenation and combination therapies
- Steroid-sparing strategies to reverse corticosteroid-induced skin damage
- Biostimulatory injectables/mesotherapy for pigmentary disorders
Selected Articles
1. A Scoping Review of Radiofrequency Microneedling: Clinical Application and Outcome Assessment.
This scoping review maps where and how RFM is used for facial rejuvenation and summarizes outcome assessments. It highlights the enhanced effects of combining RFM with agents such as poly-L-lactic acid, polynucleotides, PRP, or TCA and emphasizes using both patient-reported and objective measures to guide personalized protocols.
Impact: Provides a field-wide synthesis that can standardize assessment and inform combination strategies for RFM in aesthetic practice.
Clinical Implications: Clinicians can consider RFM across multiple facial regions and leverage combinations (e.g., PLLA, polynucleotides, PRP, TCA) to augment collagen remodeling, while adopting standardized subjective and objective outcome measures.
Key Findings
- RFM is applied to cheeks, periorbital areas, mandible, lower face, neck, and photoaged skin.
- Combining RFM with poly-L-lactic acid, polynucleotides, platelet-rich plasma, or trichloroacetic acid can enhance outcomes via collagen synthesis and repair.
- Outcome assessments span subjective patient satisfaction and objective clinical evaluations, enabling personalized treatment strategies.
Methodological Strengths
- Broad database search (PubMed, Web of Science, Embase) with anatomical region–specific synthesis
- Integrates combination-therapy evidence and categorizes subjective/objective outcomes
Limitations
- Scoping review design without quantitative meta-analysis limits effect size estimation
- Heterogeneity in protocols and outcome measures across included studies
Future Directions: Prospective RCTs with standardized RFM parameters and harmonized outcome scales; mechanistic studies of synergy with PLLA, polynucleotides, PRP, and acids.
This scoping review comprehensively evaluates the role of radiofrequency microneedling (RFM) in facial rejuvenation, focusing on its applications across specific anatomical regions, integration with transdermal drug delivery and outcome assessments. Searching on PubMed, Web of Science and Embase indicates that RFM is multifunctional in the treatment of cheeks, periorbital regions, mandible, lower face, neck and photoaging. The combination of RFM with agents like poly-L-lactic acid, polynucleotides, platelet-rich plasma and trichloroacetic acid further enhances treatment outcomes, promoting collagen synthesis and skin repair. The outcome assessment used to assess the efficacy and safety of RFM treatment were concluded, which were categorized into subjective (patient satisfaction) and objective (clinical evaluations) measures, provide a comprehensive understanding of efficacy and guide personalized treatment strategies. This review highlights RFM's significant potential as a versatile and effective tool in facial rejuvenation.Level of Evidence I This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
2. Corticosteroid-induced skin damage improved with pimecrolimus cream 1% treatment: a 1-year study in adults with mild to moderate atopic dermatitis.
In a 48–52-week cohort of adults with AD and TCS-induced facial/cubital skin damage, intermittent pimecrolimus 1% cream led to a 30.5% improvement in dermatoscopic scores and reversal of atrophy/telangiectasia in about half of patients.
Impact: Suggests a steroid-sparing option that may reverse established steroid-induced skin damage in sensitive areas, addressing a common cosmetic concern in AD management.
Clinical Implications: Consider intermittent pimecrolimus 1% cream for patients with TCS-induced atrophy/telangiectasia, especially on the face, while monitoring response with standardized imaging and balancing eczema control.
Key Findings
- Dermatophot dermatoscopic score improved by 30.5% from baseline after intermittent pimecrolimus treatment over 48–52 weeks.
- Approximately half of patients showed reversal of TCS-induced skin atrophy and telangiectasia.
- Objective imaging (dermatoscopy; ultrasound in a subset) was used to document changes in skin structure.
Methodological Strengths
- Long follow-up duration (48–52 weeks) in a real-world cohort
- Objective, device-based assessments (dermatoscopy; ultrasound subset)
Limitations
- Single-arm, nonrandomized design without a control group
- Ultrasound data were only available in a small subset (n=11)
Future Directions: Randomized controlled trials comparing pimecrolimus with TCS taper/withdrawal and other calcineurin inhibitors; histologic and biomarker studies to elucidate reversal mechanisms.
BACKGROUND AND OBJECTIVES: Long-term treatment with topical corticosteroids (TCS) can lead to skin atrophy and telangiectasia at the application site. The objective of this study was to investigate if reversal of TCS-induced skin damage in patients with atopic dermatitis (AD) can be achieved by treatment with pimecrolimus cream 1%, especially in sensitive skin areas like the face. METHODS: Forty-one adult patients with mild to moderate atopic dermatitis and preexisting moderate TCS-induced skin damage on the face and cubital areas were intermittently treated for 48-52 weeks with pimecrolimus cream 1%. Skin atrophy and telangiectasia were evaluated by a dermatoscope connected to a digital camera (Dermatophot). In 11 patients skin thickness was measured by ultrasound. RESULTS: Compared with baseline, the Dermatophot score improved by 30.5% ( CONCLUSION: Reversal of TCS-induced skin atrophy/telangiectasia was observed in approximately 1/2 of patients using chronic intermittent treatment with pimecrolimus cream 1%.
3. Clinical Analysis of PRP Combined With Hyaluronic Acid Mesotherapy in the Treatment of Facial Chloasma.
In 57 patients with chloasma, PRP+HA mesotherapy outperformed PRP or HA alone across MASI reduction and pigment-related indices at 4 weeks. Satisfaction was higher in the PRP+HA group than HA alone, and no serious adverse events were reported.
Impact: Provides comparative clinical evidence supporting a combination biostimulatory strategy for a challenging pigmentary condition with favorable short-term safety.
Clinical Implications: PRP+HA mesotherapy can be considered for chloasma to enhance early improvements in MASI and pigmentation metrics; clinicians should counsel on the preliminary 4-week horizon and plan longer-term maintenance.
Key Findings
- At 4 weeks, effective rates exceeded 50% in both PRP and PRP+HA groups.
- PRP+HA showed greater improvement than PRP or HA alone across MASI reduction and pigment degree/area/quantity indices.
- Patient satisfaction was higher in PRP+HA than HA alone; no serious adverse reactions were observed in any group.
Methodological Strengths
- Three-arm comparative design enables benchmarking of combination versus monotherapy
- Multiple quantitative endpoints (MASI, pigment indices) plus satisfaction and safety monitoring
Limitations
- Nonrandomized allocation with small group sizes and short 4-week follow-up
- Single-center design limits generalizability and durability assessment
Future Directions: Conduct randomized, blinded trials with longer follow-up to assess durability and optimal dosing schedules; include objective imaging/colorimetry and stratify by baseline melasma severity and skin phototype.
OBJECTIVE: To study the safety and clinical effect of PRP combined with hyaluronic acid (HA) mesotherapy in the treatment of facial chloasma, to explore a safe and effective treatment option for chloasma. METHODS: 57 patients with chloasma who received mesotherapy were analyzed in this study. They were divided into 19 cases of the PRP combined with HA mesotherapy group (PRP+HA group), 20 cases of the PRP mesotherapy group (PRP group) and 18 cases of the hyaluronic acid mesotherapy group (HA group). The therapeutic effect of chloasma was evaluated at the fourth week after treatment, including the decrease rate of chloasma area and severity index (MASI), the effective rate, the decrease rate of pigment degree, the decrease rate of pigment area, and the decrease rate of pigment quantity. The patient's satisfaction and adverse reactions were investigated. The safety and efficacy of each group were compared and analyzed. RESULTS: The effective rate of chloasma treatment in the PRP group and the PRP+HA group was more than 50% at 4 weeks after treatment. The improvement of the above indexes in the PRP+HA group was better than those in the single treatment group. The satisfaction of the PRP+HA group was higher than that of the HA group, and the satisfaction of the other groups was not significantly different. There were no serious adverse reactions in the three groups. CONCLUSION: PRP mesotherapy alone or combined with HA and PRP mesotherapy can effectively treat chloasma, and the combined treatment effect is better, which is worthy of clinical promotion.